Clinical trials: Cancer of the Esophagus
Resectable Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
This trial is conducted in patients with resectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 46 patients with resectable locally advanced esophageal cancer in Tianjin cancer hospital.
- Trial name
- NCT07457528
- Testing
- HLX10, Chemotherapy, Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer, Esophagectomy
PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies
Esophageal cancer ranks as the seventh leading cause of cancer globally, with 604,100 new cases, and the sixth leading cause of cancer-related deaths worldwide.
- Conditions
- Esophageal Cancer, Esophagectomy, Multimodal Analgesia, Minimally Invasive Surgery
- Trial name
- PACEMIE (NCT07434739)
- Testing
- paravertebral catheter analgesia, Epidural group
- Where
- France
- Volunteers
- 506 people
- Sponsor
- University Hospital, Lille
Esophageal Squamous Cell Carcinoma
Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer
The aim of this study was to detect the whole genome hydroxymethylation of peripheral blood ct DNA in normal population, patients with p0~pI esophageal squamous cell carcinoma and pII~pIV esophageal squamous cell carcinoma by…
- Trial name
- NCT03922230
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Hypoxia, Esophageal Cancer
COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing gastrointestinal endoscopy with propofol. This is particularly true for obese patients, who have a higher incidence of hypoxia.
- Conditions
- Hypoxia, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06796764
- Testing
- the COMBO Endoscopy Oropharyngeal Airway Group, Regular Nasal Cannula
- Where
- 3 sites in China
- Volunteers
- 580 people
- Sponsor
- Zhejiang University
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Esophageal Squamous Cell Carcinoma
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
Tislelizumab combined with chemotherapy sequential neoadjuvant therapy for non-cCR patients after neoadjuvant chemoradiotherapy in locally advanced ESCC.
- Trial name
- ETNT (NCT05189730)
- Testing
- Tirelizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Squamous Cell Carcinoma
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma with low…
- Trial name
- NCT05919030
- Testing
- Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Renmin Hospital of Wuhan University
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Gastrointestinal Cancer, Gastric Cancer
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Esophageal Cancer, Appendiceal Cancer
- Trial name
- NCT07124351
- Testing
- CYTALUX™ (pafolacianine)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cedars-Sinai Medical Center
Esophagus Cancer
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy
- Trial name
- NCT07019181
- Testing
- Tislelizumab, albumin-bound paclitaxel, Nedaplatin
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Esophageal Squamous Cell Carcinoma, Chemoradiation
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
This clinical trial has two stages: phase II and phase III. Eligible patients will be randomized 1:1 to the two arms: paclitaxel plus cisplatin and cisplatin plus 5-fluorouracil.
- Trial name
- NCT03623737
- Testing
- neoadjuvant chemoradiation
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- National Taiwan University Hospital
Solid Tumors, Metastatic Melanoma
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04140500
- Testing
- RO7247669
- Where
- 25 sites in Denmark, Georgia and 7 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Biliary Tract Diseases, Stomach Neoplasms
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
Purpose: To assess the utility of a new medical device that monitors a patient's breathing during medical procedures in which a patient is sedated, but not mechanically ventilated.
- Conditions
- Biliary Tract Diseases, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Barrett Esophagus
- Trial name
- NCT02310230
- Testing
- ExSpiron Respiratory Variation Monitor
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Donald Mathews
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Esophageal Carcinoma
mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus
There are few studies about 2nd line treatment in advanced esophageal carcinoma (AEC), some showed that irinotecan may be effective.
- Trial name
- NCT01486992
- Testing
- mFOLFIRI+Nimotuzumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Esophageal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002711
- Testing
- chemotherapy, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
The investigators are doing this research program to find out if the investigational drug, afatinib which is a medication known to block the function of the ErbB2 protein might help standard chemotherapy, in particular…
- Conditions
- HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer, Esophageal Cancer
- Trial name
- NCT02274012
- Testing
- Afatinib, Paclitaxel
- Sponsor
- Columbia University
Metastatic Esophageal Cancer
Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.
- Trial name
- NCT02843581
- Testing
- Cryosurgery, NK immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Resectable Esophageal Cancer, GastroEsophageal Cancer
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
This is a 2 part Phase I/II clinical trial evaluating the safety, tolerability and efficacy of avelumab in combination with chemoradiation in patients with resectable esophageal and gastroesophageal cancer.
- Trial name
- NCT03490292
- Testing
- Avelumab combined with Chemoradiation, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III
HEARTS Trial for Thoracic Cancers
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the…
- Conditions
- Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III
- Trial name
- NCT07132918
- Testing
- MRgART, LINAC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.